FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is a medical We are pleased to inform you that the paper search AI “Amanogawa” and the drug discovery support AI “Cascade Eye” have been introduced.

　Amanogawais a paper search AI system that uses FRONTEO's unique natural language processing AI technology.When you enter words, sentences, hypotheses, etc. that you want to look up, AI^{* 1}Instantly detect related papers from the data of more than 3000 million papers published in. By utilizing AI, in addition to greatly improving the efficiency of paper search and analysis, which required a huge amount of time for human work, information that could not be found by conventional keyword search and bias by searchers It makes it possible to find information that is not available, and realizes objective and comprehensive analysis in medical and drug discovery research.

　Cascade Eyeis an AI system that visualizes information on molecules and genes related to diseases to be analyzed in the form of a pathway map (a diagram showing relationships) based on a huge amount of paper information.The relationship between molecules and genes can be grasped instantly, and the target search process in drug discovery is greatly streamlined. Identification of previously unknown biomarkers, personalized medicine and unmet medical needs^{* 2}We support innovative drug discovery approaches, such as research related to diseases with high drug discovery rates.

　Amanogawa and Cascade Eye will be used in the company's drug discovery and health food development departments.

Comment from Mr. Toshihiro Kunigami, Director of Drug Discovery Research Laboratories, Nippon Chemiphar Co., Ltd.
　“In recent years, the productivity of drug development has been significantly declining due to a decline in the probability of success in new drug development, soaring development costs, and the increasing complexity of disease-causing target proteins. The introduction of both the Amanogawa and Cascade Eye systems is one of the solutions to these problems. We look forward to improving the accuracy of drug repositioning for our pharmaceuticals and drug candidate compounds.”

　FRONTEO will contribute to improving the quality of medical care and QOL of patients through support for improving the efficiency and probability of success of drug discovery research and business using natural language processing AI.

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

*1 Biomedical article database created by the National Center for Biological Science Information in the U.S. National Library of Medicine
*2 Strong demand for new drugs and treatments for diseases for which no effective treatments have been found.

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that uses the in-house developed AI engines KIBIT and Concept Encoder, Looca Cross specialized in natural language processing to extract meaningful and significant information from a large amount of textual data and support companies' business. Since its inception in August 2003, we have been working globally with Japan, the United States, Korea, and Taiwan, mainly in the Legaltech business, such as e-discovery (electronic evidence disclosure) and digital forensic surveys, which support company international lawsuits. Based on AI technology developed in this project, we have expanded our business fields to life science, business intelligence, and economic security since 8, and have used AI to transform textual data into knowledge, thus contributing to the resolution of various companies' issues, including support for drug discovery, support for dementia diagnostics, and support for financial, human resources, and business. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. In January 6, the company obtained a license to manufacture and sell Class I medical devices (license number: 26B2021X1), and in September of the same year, the company submitted a notification to sell controlled medical devices (notification number: 13MinatoMiSeikikiDai1). Capital: ¥10350 (as of March 9, 3).

* FRONTEO, Amanogawa, Cascade Eye, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.